- Home
- VFC vs PRAX Comparison
VFC vs PRAX Comparison
Compare VFC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VFC | PRAX |
|---|---|---|
| Founded | 1899 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 7.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | VFC | PRAX |
|---|---|---|
| Price | $19.15 | $277.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 14 |
| Target Price | $15.86 | ★ $373.79 |
| AVG Volume (30 Days) | ★ 5.7M | 745.2K |
| Earning Date | 01-28-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $9,541,055,000.00 | $7,463,000.00 |
| Revenue This Year | $0.73 | N/A |
| Revenue Next Year | $0.57 | $12,467.71 |
| P/E Ratio | $81.30 | ★ N/A |
| Revenue Growth | N/A | ★ 364.98 |
| 52 Week Low | $9.41 | $26.70 |
| 52 Week High | $29.02 | $317.72 |
Technical Indicators
Market Signals| Indicator | VFC | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 63.13 | 59.04 |
| Support Level | $17.90 | $285.95 |
| Resistance Level | $18.38 | $317.72 |
| Average True Range (ATR) | 0.53 | 13.17 |
| MACD | -0.10 | -3.44 |
| Stochastic Oscillator | 87.30 | 25.89 |
Price Performance
Historical ComparisonAbout VFC V.F. Corporation
VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of 10 brands includes Vans, The North Face, Timberland, and Altra. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.